{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen Y"],"funding":["Pancreatic Cancer Action Network","NCI NIH HHS","National Institutes of Health"],"pagination":["606-608"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10911497"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(8)"],"pubmed_abstract":["Immunotherapy has been a paradigm shift in cancer treatment to produce durable responses. Unfortunately, most cancers do not respond to current immunotherapies, and thus, exploring novel mechanisms is crucial. Emerging data now demonstrate that protein modification by the small ubiquitin-like modifiers (SUMO) is a novel target to activate antitumor immunity."],"journal":["Trends in cancer"],"pubmed_title":["A new immuno-oncology target - SUMOylation."],"pmcid":["PMC10911497"],"funding_grant_id":["R01 CA265410","R01CA216987","R01 CA212119","R01CA265410","R01 CA216987"],"pubmed_authors":["Chen Y"],"additional_accession":[]},"is_claimable":false,"name":"A new immuno-oncology target - SUMOylation.","description":"Immunotherapy has been a paradigm shift in cancer treatment to produce durable responses. Unfortunately, most cancers do not respond to current immunotherapies, and thus, exploring novel mechanisms is crucial. Emerging data now demonstrate that protein modification by the small ubiquitin-like modifiers (SUMO) is a novel target to activate antitumor immunity.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2024-11-09T06:21:26.536Z","creation":"2024-11-09T06:21:26.536Z"},"accession":"S-EPMC10911497","cross_references":{"pubmed":["37179168"],"doi":["10.1016/j.trecan.2023.04.010"]}}